rhBNP Inhibits Ferroptosis in Renal Ischemia-Reperfusion Injury via Selenium Recycling

Study Background and Research Question

Acute kidney injury (AKI), particularly in intensive care settings, remains a leading cause of morbidity and mortality, with renal ischemia-reperfusion (IR) injury being a major contributor. Despite progress in supportive management, there is a lack of targeted therapies for renal IR injury. Recombinant human brain natriuretic peptide (rhBNP) has shown renoprotective effects in some settings, principally via hemodynamic mechanisms, but its role in modulating cell death pathways during ischemic injury has not been fully clarified. This study sought to determine whether rhBNP could attenuate IR-induced AKI by influencing ferroptosis, a regulated form of cell death characterized by iron-dependent lipid peroxidation, and to elucidate the underlying mechanism (reference study).

Key Innovation from the Reference Study

The central innovation of this research is the identification of selenium recycling, specifically via upregulation of selenocysteine lyase (SCLY), as a mechanistic link between rhBNP treatment and inhibition of ferroptosis in renal IR injury. By integrating transcriptomic analysis and targeted molecular interventions, the study demonstrates that rhBNP not only improves gross renal outcomes but also modulates a distinct metabolic pathway—selenium utilization and selenoprotein synthesis—thereby limiting oxidative cell death in the kidney.

Methods and Experimental Design Insights

• Clinical Cohort: rhBNP administration was evaluated in ICU patients with AKI for its impact on renal recovery and disease progression.
• Preclinical Models: Rat models of renal IR injury received rhBNP treatment, and kidney function, histological injury, and markers of cell death were assessed.
• Transcriptomic Analysis: RNA sequencing identified differentially expressed genes in kidneys from rhBNP-treated animals, pinpointing SCLY as a key node.
• Loss- and Gain-of-Function Studies: In vivo and in vitro (human HK2 cell) models with SCLY knockdown or overexpression elucidated its causal role in mediating rhBNP effects.
• Mechanistic Assays: Selenium content, selenoprotein levels, ferroptosis (lipid peroxidation, GPX activity), and apoptosis markers were systematically quantified.
• Protein Interaction Studies: The impact of rhBNP on the interaction between GTPase RhoA and SCLY was explored to reveal regulatory mechanisms.

Core Findings and Why They Matter

The study demonstrates several interrelated findings:

• rhBNP administration improved renal function and limited AKI progression in both ICU patients and rat models following IR injury, indicating clinical and preclinical efficacy.
• Transcriptomic profiling revealed that SCLY, an enzyme central to recycling selenium for selenoprotein biosynthesis, was robustly upregulated by rhBNP treatment.
• Enhanced SCLY expression led to elevated renal selenium levels and increased synthesis of selenoproteins, including the antioxidant enzyme glutathione peroxidase (GPX).
• rhBNP suppressed ferroptosis and apoptosis in renal tissue, effects that were reversed upon SCLY knockdown and further potentiated with SCLY overexpression.
• Mechanistically, rhBNP appeared to inhibit the binding of active RhoA to SCLY, promoting SCLY stability and function.

These findings underscore a novel axis in which the modulation of selenium metabolism—and by extension, selenoprotein-mediated antioxidative defense—serves as a critical determinant of cell fate following ischemic kidney injury. The identification of SCLY as a target provides a rationale for therapies that enhance selenium recycling to mitigate ferroptotic damage in AKI.

Protocol Parameters

• rhBNP administration in rat IR model: Typically given at the onset of reperfusion; consult original methods for dosing and timing.
• SCLY knockdown/overexpression: In vivo or in vitro gene modulation performed by siRNA or expression vectors; validate efficiency prior to endpoint analyses.
• Assessment of ferroptosis: Quantify lipid peroxidation (MDA), GPX activity, and selenoprotein levels as indicators of ferroptotic inhibition.

Comparison with Existing Internal Articles

While the reference study focuses on selenium metabolism and ferroptosis in renal IR injury, internal articles such as "U 46619: Advanced Insights Into Prostaglandin Signaling for Cardiovascular and Renal Research" and "U 46619: Selective Agonist for Platelet Aggregation and Vascular Models" address the use of synthetic agonists like U 46619 (11,9 epoxymethano-prostaglandin H2) in modulating vascular tone, platelet aggregation, and renal hemodynamics. Notably, U 46619 is widely used as a platelet aggregation inducer and for studying renal cortical vasoconstriction—processes that overlap with the hemodynamic aspects of AKI but not with the selenium/ferroptosis axis identified in the current paper.

This divergence highlights the complementary approaches: while prostaglandin analogues and TP receptor agonists such as U 46619 dissect G-protein coupled signaling in vascular and platelet biology (see internal reference), the present study extends mechanistic understanding to metabolic and redox regulation within the kidney during IR injury.

Limitations and Transferability

Despite the robust mechanistic evidence, several limitations warrant discussion. The clinical dataset, while suggestive, is observational and requires validation in randomized controlled trials. Most mechanistic experiments are in preclinical (rat) or in vitro (HK2 cell) models; transferability to human AKI pathophysiology remains to be fully established. The focus on the SCLY pathway does not exclude the involvement of other selenium-related or ferroptosis-independent mechanisms in the renal response to IR injury.

Furthermore, the interaction between hemodynamic modulators (e.g., TP receptor agonists) and selenium/ferroptosis pathways is not directly addressed and represents an area for future exploration.

Research Support Resources

Researchers aiming to model vascular, platelet, or renal hemodynamic responses related to AKI and IR injury may benefit from integrating pharmacological tools that target G-protein coupled receptor pathways. U 46619 (SKU B6890) from APExBIO, a synthetic analogue of prostaglandin H2 (11,9 epoxymethano-prostaglandin H2), is routinely used as a selective agonist of prostaglandin H2/thromboxane A2 receptors, facilitating studies of platelet function, serotonin release in platelets, and blood pressure modulation in hypertensive rats. Its solubility and validated efficacy make it suitable for controlled mechanistic research, and it can be stored at -20°C as recommended. While the current study emphasizes selenium metabolism, combining such tools with metabolic modulators will enable a more comprehensive understanding of renal injury and repair mechanisms.